BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 10719738)

  • 41. Mdm2 and the p53 pathway in human pituitary adenomas.
    Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
    [TBL] [Abstract][Full Text] [Related]  

  • 42. WAF1/p21 protein expression is an independent prognostic indicator in superficial and invasive bladder cancer.
    Korkolopoulou P; Konstantinidou AE; Thomas-Tsagli E; Christodoulou P; Kapralos P; Davaris P
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):285-92. PubMed ID: 11127920
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic value of simultaneous expression of p21 and mdm2 in breast carcinomas treated by adjuvant chemotherapy with antracyclin.
    Mathoulin-Portier MP; Viens P; Cowen D; Bertucci F; Houvenaeghel G; Geneix J; Puig B; Bardou VJ; Jacquemier J
    Oncol Rep; 2000; 7(3):675-80. PubMed ID: 10767389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load.
    Helland A; Karlsen F; Due EU; Holm R; Kristensen G; Børresen-Dale Al
    Br J Cancer; 1998 Jul; 78(1):69-72. PubMed ID: 9662253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer.
    Stein JP; Ginsberg DA; Grossfeld GD; Chatterjee SJ; Esrig D; Dickinson MG; Groshen S; Taylor CR; Jones PA; Skinner DG; Cote RJ
    J Natl Cancer Inst; 1998 Jul; 90(14):1072-9. PubMed ID: 9672255
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High expression of MDM2 protein and low rate of p21(WAF1/CIP1) expression in SCID mice Epstein Barr virus-induced lymphoproliferation.
    El Mansouri S; Martin A; Mercadier A; Capoulade C; Maréchal V; Wiels J; Feuillard J; Raphaël M
    J Histochem Cytochem; 1999 Oct; 47(10):1315-22. PubMed ID: 10490460
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
    Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
    Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular abnormalities of the p53 pathway in dedifferentiated liposarcoma.
    Dei Tos AP; Doglioni C; Piccinin S; Maestro R; Mentzel T; Barbareschi M; Boiocchi M; Fletcher CD
    J Pathol; 1997 Jan; 181(1):8-13. PubMed ID: 9071997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical expression of mdm2 and p21WAF1 in invasive cervical cancer: correlation with p53 protein and high risk HPV infection.
    Troncone G; Martinez JC; Palombini L; De Rosa G; Mugica C; Rodriguez JA; Zeppa P; Di Vizio D; Lucariello A; Piris MA
    J Clin Pathol; 1998 Oct; 51(10):754-60. PubMed ID: 10023338
    [TBL] [Abstract][Full Text] [Related]  

  • 52. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
    Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
    J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
    Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alterations of cell cycle regulators in localized synovial sarcoma: A multifactorial study with prognostic implications.
    Antonescu CR; Leung DH; Dudas M; Ladanyi M; Brennan M; Woodruff JM; Cordon-Cardo C
    Am J Pathol; 2000 Mar; 156(3):977-83. PubMed ID: 10702413
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
    Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
    J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Loss of p21Waf1 expression is a strong predictor of reduced survival in primary superficial bladder cancers.
    Migaldi M; Sgambato A; Garagnani L; Ardito R; Ferrari P; De Gaetani C; Cittadini A; Trentini GP
    Clin Cancer Res; 2000 Aug; 6(8):3131-8. PubMed ID: 10955794
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
    Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
    Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
    Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
    Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. p53 gene status and expression of p53, mdm2, and p21Waf1/Cip1 proteins in colorectal cancer.
    Veloso M; Wrba F; Kaserer K; Heinze G; Magalhães A; Herbst F; Teleky B
    Virchows Arch; 2000 Sep; 437(3):241-7. PubMed ID: 11037343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
    Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.